UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin
Portfolio Pulse from Lara Goldstein
A Phase 1 clinical trial led by UCSF assessing Filament Health Corp.'s (OTCQB:FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes. The trial administered doses of naturally-sourced psilocybin and psilocin to four healthy subjects, reporting good tolerability and no serious adverse events.
May 31, 2023 | 12:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Filament Health Corp.'s Phase 1 clinical trial led by UCSF shows positive interim outcomes for its botanical psychedelic drug candidates, potentially boosting investor confidence.
The positive interim outcomes from the Phase 1 clinical trial indicate that Filament Health Corp.'s drug candidates are well-tolerated and show no serious adverse events. This news is likely to boost investor confidence in the company's ability to develop and standardize naturally-derived psychedelic medicines, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100